Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer

Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer

The prognosis of patients with metastatic colorectal cancer (mCRC) who progressed to the first and the second lines of treatment is poor. Thus, new therapeutic strategies are needed. During the last years, emerging evidence suggests that retreatment with anti-epidermal growth factor receptor (EGFR)...

Full description

Bibliographic Details
Main Authors: Davide Ciardiello, Giulia Martini, Vincenzo Famiglietti, Stefania Napolitano, Vincenzo De Falco, Teresa Troiani, Tiziana Pia Latiano, Javier Ros, Elena Elez Fernandez, Pietro Paolo Vitiello, Evaristo Maiello, Fortunato Ciardiello, Erika Martinelli
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
rechallenge
anti-EGFR monoclonal antibodies
metastatic colorectal cancer
Online Access:https://www.mdpi.com/2072-6694/13/8/1941

Internet

https://www.mdpi.com/2072-6694/13/8/1941

Similar Items